Aurinia Pharmaceuticals Inc. 8-K

What Happened

• Aurinia Pharmaceuticals (AUPH) filed a Form 8-K reporting a management transition: the Board appointed Kevin Tang as Chief Executive Officer (principal executive officer) effective March 23, 2026. At the same time the Board appointed Ryan Cole as Chief Operating Officer and Michael Hearne as Chief Financial Officer (principal financial and accounting officer), all effective March 23, 2026.
• Prior officers — Peter Greenleaf (President, CEO and Director), Matthew Donley (COO), Gregory Keenan, M.D. (CMO), and Joseph Miller (CFO) — ceased serving as officers effective March 20, 2026. Mr. Greenleaf resigned from the Board effective March 21, 2026 and will serve as a consultant for three months at $600 per hour. The Board also created and filled a Lead Independent Director role, electing Craig Johnson effective March 21, 2026.

Key Details

• Kevin Tang (age 59) has served as Aurinia’s Board Chair since 2024 and is founder/president of Tang Capital Management; he has experience founding/co-founding several life-science companies. Mr. Tang has elected not to receive salary, bonuses, equity awards, or other compensation from Aurinia.
• Ryan Cole (age 39): annual base salary $300,000; target bonus 50% of base salary; granted a new-hire option to purchase 150,000 common shares.
• Michael Hearne (age 63): annual base salary $300,000; target bonus 50% of base salary; granted a new-hire option to purchase 150,000 common shares.
• No arrangements or understandings with third parties were disclosed regarding the appointments; none of the three appointees have family relationships with Aurinia directors/officers or reportable related-party transactions under Item 404(a) of Regulation S-K.

Why It Matters

• This is a material leadership change: the company replaced its CEO, COO, CFO and other senior officers and installed an experienced life‑science executive (Kevin Tang) as CEO. Management changes can affect strategy, execution, investor communications and operational priorities.
• New executive compensation (salaries, target bonuses and equity options) and the consulting fee for the outgoing CEO are concrete items investors can track for their impact on cash burn and potential share dilution. Investors should watch subsequent filings and press releases for strategic updates, guidance changes, and any further governance or operational plans from the new leadership.